Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 3;5:16053. doi: 10.1038/srep16053

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) Serial whole tumor sections from 67 NSCLC patients were used and representative cases of immunostaining of IL-17, GIV and CD34 (MVD) are shown (magnification, 200×). (b,c) Significant positive correlations were found between the GIV expression and MVD (b), GIV expression and IL-17-positive cells intensity (c). (d,e) Kaplan-Meier curves of overall survival analysis between NSCLC patients. GIV (d) or IL-17(e) with high expression patients had significantly poorer OS than low expression patients. (f) NSCLC patients were classified into three groups: group I, high expression both of IL-17+ cells and GIV; group II, high expression of one of the two markers; and group III, low expression of both markers. The 3 year survival rates in group I were significantly lower than those in groups II and III. P values were determined by log-rank test.